Information Provided By: 
Fly News Breaks for February 7, 2020
ENTA
Feb 7, 2020 | 10:19 EDT
Enanta Pharmaceuticals is "undervalued and underappreciated," Roth Capital analyst Yasmeen Rahimi tells investors in a post-earnings research note. The company's current market capitalization of $1.12B despite its $417M cash in pocket, four pipeline opportunities and "steady stream" of hepatitis C virus royalty, contends the analyst. Rahimi calls Enanta one of the most undervalued companies she covers. The analyst keeps a Buy rating on the shares with a $130 price target. The stock in early trading is down 3% to $53.92.
News For ENTA From the Last 2 Days
There are no results for your query ENTA
